Alipogene tiparvovec

Drug Profile

Alipogene tiparvovec

Alternative Names: AMT-010; AMT-011; AMT-11; Glybera; LPL gene therapy - AMT

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Developer Chiesi Farmaceutici; uniQure
  • Class Antihyperlipidaemics; Gene therapies
  • Mechanism of Action Gene transference; Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type I
  • Discontinued Hyperlipoproteinaemia type V

Most Recent Events

  • 22 Sep 2017 Discontinued - Phase-I/II for Hyperlipoproteinaemia type V in European Union (IM), because there have been no recent reports on development in this indication
  • 21 Sep 2017 Discontinued - Phase-II/III for Hyperlipoproteinaemia type I in Canada (IM), because not listed in uniQure pipeline, September 2017
  • 20 Jul 2017 UniQure Biopharma and Chiesi Farmaceutici withdraw a phase II trial for Hyperlipoproteinaemia type I prior to enrolment in USA and Canada, as uniQure has decided not to renew the marketing authorisation of Alipogene tiparvovec in the European Union (NCT02904772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top